Cereno Scientific AB
Cereno Scientific AB is a pre-revenue, clinical-stage Swedish biotech developing epigenetic HDAC-inhibitor therapies (CS1, CS014, CS585) for rare cardiovascular and pulmonary diseases such as PAH, PH-ILD, and rare thrombotic disorders, with lead candidate CS1 in global Phase IIb preparation under FDA Fast Track and Orphan Drug Designations.
- Company typePublic
- Founded2016
- HeadquartersMölndal, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cereno Scientific AB does
Cereno Scientific AB is a clinical-stage Swedish biotechnology company developing disease-modifying therapies for rare cardiovascular and pulmonary diseases using epigenetic modulation through histone deacetylase (HDAC) inhibition. The company's pipeline comprises three drug candidates: CS1, a controlled-release oral once-daily HDAC inhibitor in global Phase IIb preparation for pulmonary arterial hypertension (PAH), which holds FDA Fast Track and Orphan Drug Designations in both the US and Europe; CS014, a next-generation HDAC inhibitor that has completed Phase I with favorable safety and is being expanded into pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a Phase IIb planned for Q1 2027; and CS585, a preclinical selective prostacyclin (IP) receptor agonist for rare thrombotic disorders being advanced with the University of Michigan.
The company targets indications with high unmet medical need where current therapies address only vasodilation or symptom relief without modifying underlying disease biology, and aims to differentiate on disease-modifying potential such as reverse vascular remodeling, anti-fibrotic effects, and antithrombotic activity without increased bleeding risk. Operationally, Cereno operates a lean model of 1-10 employees with a headquarters in Mölndal (Gothenburg), Sweden, a US subsidiary in Cambridge, Massachusetts, and outsourced clinical execution through a leading global CRO. The company is listed on Nasdaq First North Growth Market (CRNO B) and has funded operations to date through equity issuances, including a 2016 IPO, 2019 and 2023 rights issues, a 2020 directed issue, and approximately $87M raised across 2024-2025 from investors including Arena Investors, Fenja Capital, SAJ Finans, and Venusat. The business model is pre-revenue: there are no commercialized products, and the stated commercialization pathway relies on entering pharma partnerships following Phase IIb value-inflection milestones.
Cereno Scientific AB firmographics
Firmographics- Name
- Cereno Scientific AB
- Legal name
- Cereno Scientific AB (publ)
- Website
- https://cerenoscientific.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cereno Scientific AB is a pre-revenue, clinical-stage Swedish biotech developing epigenetic HDAC-inhibitor therapies (CS1, CS014, CS585) for rare cardiovascular and pulmonary diseases such as PAH, PH-ILD, and rare thrombotic disorders, with lead candidate CS1 in global Phase IIb preparation under FDA Fast Track and Orphan Drug Designations.
- Ownership category
- akta.pro rank
Cereno Scientific AB industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
Keywords
Where Cereno Scientific AB is headquartered
LocationHeadquarters
- HQ city
- Mölndal
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Cereno Scientific AB business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Distribution channels2 records
Marketing channels5 records
Cereno Scientific AB product offering
Product offeringCore offering
Cereno Scientific AB is a clinical-stage biotech company developing disease-modifying drug candidates for rare cardiovascular and pulmonary diseases. Its pipeline consists of CS1, an oral once-daily HDAC inhibitor for pulmonary arterial hypertension (PAH); CS014, a next-generation HDAC inhibitor for pulmonary hypertension associated with interstitial lung disease (PH-ILD); and CS585, a prostacyclin (IP) receptor agonist in preclinical development for rare thrombotic disorders. The company has no commercialized products and intends to monetize the pipeline through pharmaceutical partnerships.
Product overview
Cereno Scientific is a clinical-stage biotech company developing disease-modifying therapies for rare cardiovascular and pulmonary diseases through epigenetic modulation using HDAC inhibitors. The company's pipeline consists of three drug candidates: CS1 (Phase IIb preparation for PAH using HDAC inhibition with FDA Fast Track and Orphan Drug Designations), CS014 (Phase I completed for PH-ILD, next-generation HDAC inhibitor with multimodal properties), and CS585 (preclinical prostacyclin receptor agonist for rare thrombotic disorders). The company is headquartered in Gothenburg, Sweden with operations in Boston, Massachusetts, and is listed on Nasdaq First North Growth Market (CRNO B).
Differentiator
Problem solved
Functional benefit
Products and services
- CS1 CS1 is an oral, once-daily controlled-release formulation of sodium valproate (an HDAC inhibitor) developed as a disease-modifying add-on therapy for pulmonary arterial hypertension (PAH). It targets disease progression through epigenetic modulation, aiming to slow, halt, or reverse PAH by reverse vascular remodeling. CS1 has received FDA Fast Track designation and Orphan Drug Designation in the US and Europe. It is intended for patients with rare, progressive, life-threatening PAH and is currently being prepared for a global Phase IIb trial.
- CS014 CS014 is a next-generation, novel chemical entity HDAC inhibitor with a multimodal mechanism in development for pulmonary hypertension associated with interstitial lung disease (PH-ILD). It is an oral, once-daily therapy that has demonstrated favorable safety and tolerability in a completed Phase I trial, with strong effects on vascular remodeling, fibrosis, and thrombosis in preclinical studies. CS014 is intended for patients with PH-ILD, a condition combining fibrotic lung pathology with pulmonary vascular disease.
- CS585
Quantifiable outcome
- Phase IIa trial successfully met primary endpoint of safety and tolerability with no drug-related serious adverse events
- +2 more outcomes
Companies that use Cereno Scientific AB
Customer profileSegments3 records
Ideal customer profiles3 records
Cereno Scientific AB technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cereno Scientific AB partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Journal of Thrombosis and HaemostasisminorPeer-reviewed publication of first manuscript on HDAC inhibitor CS014 demonstrating antithrombotic efficacy without bleeding risk in animal models.
- University of MichigancoreResearch collaboration with the University of Michigan for the development of CS585, a novel prostacyclin (IP) receptor agonist for rare thrombotic disorders. Professor Michael Holinstat, Associate Professor in Pharmacology at the University of Michigan, leads the translational programs in drug development and serves as Director of Translational Research at Cereno.
- FluiddaminorCollaboration using Functional Respiratory Imaging (FRI) technology for the Expanded Access Program sub-study. FRI is a non-invasive imaging tool providing detailed, patient-specific insights into pulmonary vascular changes to evaluate CS1's disease-modifying potential.
- Leading Global CRO (Contract Research Organization)coreCollaboration with leading international contract research organization (CRO) to conduct the global Phase IIb trial for CS1 in PAH. The multicenter trial will enroll approximately 126 patients across 10-12 countries.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Cereno Scientific AB competitors and assessment
Company assessmentDirect peers
- United Therapeutics Corporation: United Therapeutics is the dominant established commercial player in pulmonary arterial hypertension with multiple approved products including Tyvaso, Remodulin and Orenitram, making it the most directly comparable peer to Cereno's CS1 program in PAH.
- Liquidia Corporation: Liquidia is a US rare-disease company with an FDA-approved inhaled treprostinil product (YUTREPIA) for PAH and PH-ILD, directly competing with CS1 and CS014 in Cereno's primary target indications.
- Aerovate Therapeutics: Aerovate is a clinical-stage pulmonary hypertension biotech advancing an inhaled imatinib (AV-101) for PAH, sharing a small-cap PAH development profile, regulatory designations, and the same addressable population as Cereno's CS1.
- Pliant Therapeutics: Pliant Therapeutics is a clinical-stage biotech developing therapies for fibrotic lung diseases including IPF and PH-ILD with integrin-based mechanisms, competing for the same rare pulmonary patient population as Cereno's CS014 program.
- Gossamer Bio: Gossamer Bio is a clinical-stage biopharmaceutical company focused on immune-mediated cardiopulmonary diseases including PAH and PH-ILD, making it a direct comparable in target indications and mechanism-of-action profile to Cereno's CS1 and CS014.
Broad incumbents
- Acceleron Pharma (a Merck company): Acceleron was a rare-disease biotech acquired by Merck for ~$11.5B largely on the strength of its PAH franchise (sotatercept/Acceleron rebadged Winrevair), serving as an aspirational comparable for clinical-stage rare cardiovascular biotechs like Cereno.
- Arena Pharmaceuticals: Arena Pharmaceuticals is a clinical-stage rare and specialty disease biotech acquired by Pfizer for ~$6.7B in 2022, providing a strategic-acquisition benchmark for clinical-stage rare-disease companies like Cereno with Phase II/III assets.
- Insmed Incorporated: Insmed is a commercial-stage rare and orphan-disease biotech with growing respiratory and cardiopulmonary franchises, serving as a scaled comparable for late-stage rare pulmonary development companies such as Cereno Scientific.
Emerging players
- Madrigal Pharmaceuticals: Madrigal Pharmaceuticals is a clinical-to-commercial rare-disease biotech with Rezdiffra for MASH, sharing a small-cap US-listed development profile, single-asset narrative, and orphan-drug commercial strategy comparable to Cereno.
- Cardior Pharmaceuticals: Cardior Pharmaceuticals is a clinical-stage European biotech developing RNA-based therapies for cardiovascular diseases including heart failure; its prior CMO Dr. Agrawal now leads R&D at Cereno, making it a closely linked sector peer in cardiology drug development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Cereno Scientific AB social profiles
Digital presenceCereno Scientific AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cereno Scientific AB leadership team
Management profileNumber of profiles
Profiles16 records
Cereno Scientific AB subsidiaries and ownership
Company hierarchySubsidiaries1 record
Cereno Scientific AB funding detail
Funding detailFunding overview
Funding rounds18 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cereno Scientific AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cereno Scientific AB
What does Cereno Scientific AB do?
Cereno Scientific AB is a clinical-stage biotech company developing disease-modifying drug candidates for rare cardiovascular and pulmonary diseases. Its pipeline consists of CS1, an oral once-daily HDAC inhibitor for pulmonary arterial hypertension (PAH); CS014, a next-generation HDAC inhibitor for pulmonary hypertension associated with interstitial lung disease (PH-ILD); and CS585, a prostacyclin (IP) receptor agonist in preclinical development for rare thrombotic disorders. The company has no commercialized products and intends to monetize the pipeline through pharmaceutical partnerships.
Is Cereno Scientific AB a public or private company?
Cereno Scientific AB is a public company. It is classified as public and is currently operating.
When was Cereno Scientific AB founded?
Cereno Scientific AB was founded in 2016. It employs 11 to 50 people.
Where is Cereno Scientific AB based?
Cereno Scientific AB is headquartered in Mölndal, Sweden, in the Europe region.
Who are Cereno Scientific AB's main competitors?
Direct peers on record are United Therapeutics Corporation, Liquidia Corporation, Aerovate Therapeutics, Pliant Therapeutics and Gossamer Bio. Broad incumbents are Acceleron Pharma (a Merck company), Arena Pharmaceuticals and Insmed Incorporated. Emerging players are Madrigal Pharmaceuticals and Cardior Pharmaceuticals.
Does Cereno Scientific AB have an API?
No public API is recorded for Cereno Scientific AB.
What industry is Cereno Scientific AB in?
Cereno Scientific AB's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.